Trial Profile
Single Site, Randomized, Double Blind, Placebo-Controlled Study to Assess the Long-Term Safety of Tafenoquine
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2021
Price :
$35
*
At a glance
- Drugs Tafenoquine (Primary)
- Indications Malaria
- Focus Adverse reactions
- Sponsors 60 Degrees Pharmaceuticals
- 19 Nov 2021 According to a 60 Degrees Pharmaceuticals media release, Results of a long-term safety study of the clinical safety and tolerability of ARAKODA (tafenoquine) have been published in Travel Medicine and Infectious Disease.
- 19 Nov 2021 Results published in the 60 Degrees Pharmaceuticals Media Release
- 25 Aug 2021 Status changed from recruiting to completed.